Compare MGIH & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MGIH | IOBT |
|---|---|---|
| Founded | 1978 | 2014 |
| Country | Hong Kong | Denmark |
| Employees | N/A | N/A |
| Industry | Publishing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.4M | 12.7M |
| IPO Year | 2022 | 2021 |
| Metric | MGIH | IOBT |
|---|---|---|
| Price | $1.44 | $0.20 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.25 |
| AVG Volume (30 Days) | 8.6K | ★ 1.4M |
| Earning Date | 10-28-2025 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.77 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $0.14 |
| 52 Week High | $4.84 | $2.79 |
| Indicator | MGIH | IOBT |
|---|---|---|
| Relative Strength Index (RSI) | 46.86 | 36.00 |
| Support Level | $1.41 | $0.14 |
| Resistance Level | $1.53 | $0.40 |
| Average True Range (ATR) | 0.05 | 0.03 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 13.04 | 37.07 |
Millennium Group International Holdings Ltd supplies paper-based packaging solutions, including inner packaging boxes produced with offset or flexo printing and outer corrugated boxes used for transportation, storage, pallets, and point-of-purchase displays. The company manufactures corrugated products of different sizes, shapes, thicknesses, and strengths according to customer specifications. It also operates a supply chain management business in Vietnam to service international clients who source their packaging needs from Vietnam and other ASEAN countries. The corrugated paper is durable, versatile, economical, and lightweight.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.